Summit Therapeutics (SMMT) Tops Q3 EPS by 4c
Tweet
Share
E-mail
Get Alerts SMMT Hot Sheet
Join SI Premium – FREE
Summit Therapeutics (NASDAQ: SMMT) reported Q3 EPS of (GBP0.13), GBP0.04 better than the analyst estimate of (GBP0.17).
For earnings history and earnings-related data on Summit Therapeutics (SMMT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Summit Therapeutics plc (SMMT) PT Raised to $9.80 at Bernstein SocGen Group
- Primoris cuts 2026 outlook on renewables cost overruns, COO exits
- BuzzFeed sells shares to Byron Allen affiliate for $5.8 million
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
